The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia
Open accessAbstract
Randomized trials of venetoclax plus anti-CD20 antibodies as first-line treatment in fit patients (i.e., those with a low burden of coexisting conditions) with advanced chronic lymphocytic leukemia (CLL) have been lacking. Download a PDF of the Research Summary. In a phase 3, open-label trial, we randomly assigned, in a 1:1:1:1 ratio, fit patients with CLL who did not have TP53 aberrations to receive six cycles of chemoimmunotherapy (fludarabine–cyclophosphamide–rituximab or bendamustine–rituximab) or 12 cycles of venetoclax–rituximab, venetoclax–obinutuzumab, or venetoclax–obinutuzumab–ibrutinib. Ibrutinib was discontinued after two consecutive measurements of undetectable minimal residual disease or could be extended. The primary end points were undetectable minimal residual disease (sensitivity, <10−4 [i.e., <1 CLL cell in 10,000 leukocytes]) as assessed by flow cytometry in peripheral blood at month 15 and progression-free survival. A total of 926 patients were assigned to one of the four treatment regimens (229 to chemoimmunotherapy, 237 to venetoclax–rituximab, 229 to venetoclax–obinutuzumab, and 231 to venetoclax–obinutuzumab–ibrutinib). At month 15, the percentage of patients with undetectable minimal residual disease was significantly higher in the venetoclax–obinutuzumab group (86.5%; 97.5% confidence interval [CI], 80.6 to 91.1) and the venetoclax–obinutuzumab–ibrutinib group (92.2%; 97.5% CI, 87.3 to 95.7) than in the chemoimmunotherapy group (52.0%; 97.5% CI, 44.4 to 59.5; P<0.001 for both comparisons), but it was not significantly higher in the venetoclax–rituximab group (57.0%; 97.5% CI, 49.5 to 64.2; P=0.32). Three-year progression-free survival was 90.5% in the venetoclax–obinutuzumab–ibrutinib group and 75.5% in the chemoimmunotherapy group (hazard ratio for disease progression or death, 0.32; 97.5% CI, 0.19 to 0.54; P<0.001). Progression-free survival at 3 years was also higher with venetoclax–obinutuzumab (87.7%; hazard ratio for disease progression or death, 0.42; 97.5% CI, 0.26 to 0.68; P<0.001), but not with venetoclax–rituximab (80.8%; hazard ratio, 0.79; 97.5% CI, 0.53 to 1.18; P=0.18). Grade 3 and grade 4 infections were more common with chemoimmunotherapy (18.5%) and venetoclax–obinutuzumab–ibrutinib (21.2%) than with venetoclax–rituximab (10.5%) or venetoclax–obinutuzumab (13.2%). Venetoclax–obinutuzumab with or without ibrutinib was superior to chemoimmunotherapy as first-line treatment in fit patients with CLL. (Funded by AbbVie and others; GAIA–CLL13 ClinicalTrials.gov number, NCT02950051; EudraCT number, 2015-004936-36.) QUICK TAKE VIDEO SUMMARYVenetoclax Combinations in CLL 02:52
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallek, M., Cheson, B. D., Catovsky, D., Caligaris-Cappio, F., Dighiero, G., Döhner, H., Hillmen, P., Keating, M. J., Montserrat, E., Rai, K. R., et al. (2008) · Blood · doi:10.1182/blood-2007-06-093906 · Cited by 3,787
Self-citationHallek, M., Fischer, K., Fingerle-Rowson, G., Fink, A., Busch, R., Mayer, J., Hensel, M., Hopfinger, G., Hess, G., von Grünhagen, U., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61381-5 · Cited by 1,888
Self-citationBinet, J. L., Auquier, A., Dighiero, G., Chastang, C., Piguet, H., Goasguen, J., Vaugier, G., Potron, G., Colona, P., Oberling, F., et al. (1981) · Cancer · doi:10.1002/1097-0142(19810701)48:1<198::aid-cncr2820480131>3.0.co;2-v · Cited by 1,778
Tumour lysis syndrome: new therapeutic strategies and classification
Cairo, M. S., & Bishop, M. (2004) · British Journal of Haematology · doi:10.1111/j.1365-2141.2004.05094.x · Cited by 1,076
Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia
Seymour, J. F., Kipps, T. J., Eichhorst, B., Hillmen, P., D’Rozario, J., Assouline, S., Owen, C., Gerecitano, J., Robak, T., De la Serna, J., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1713976 · Cited by 940
Self-citationVenetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions
Fischer, K., Al-Sawaf, O., Bahlo, J., Fink, A.-M., Tandon, M., Dixon, M., Robrecht, S., Warburton, S., Humphrey, K., Samoylova, O., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1815281 · Cited by 873
Self-citationIbrutinib–Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia
Shanafelt, T. D., Wang, X. V., Kay, N. E., Hanson, C. A., O’Brien, S., Barrientos, J., Jelinek, D. F., Braggio, E., Leis, J. F., Zhang, C. C., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1817073 · Cited by 749
Self-citationSalvi, F., Miller, M. D., Grilli, A., Giorgi, R., Towers, A. L., Morichi, V., Spazzafumo, L., Mancinelli, L., Espinosa, E., Rappelli, A., et al. (2008) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2008.01935.x · Cited by 581
Ibrutinib and Venetoclax for First-Line Treatment of CLL
Jain, N., Keating, M., Thompson, P., Ferrajoli, A., Burger, J., Borthakur, G., Takahashi, K., Estrov, Z., Fowler, N., Kadia, T., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1900574 · Cited by 509
Böttcher, S., Ritgen, M., Fischer, K., Stilgenbauer, S., Busch, R. M., Fingerle-Rowson, G., Fink, A. M., Bühler, A., Zenz, T., Wenger, M. K., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.36.9348 · Cited by 460
Self-citationIbrutinib Plus Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia: The CLARITY Study
Hillmen, P., Rawstron, A. C., Brock, K., Muñoz-Vicente, S., Yates, F. J., Bishop, R., Boucher, R., MacDonald, D., Fegan, C., McCaig, A., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.00894 · Cited by 272
CLL), O. B. O. E. (. R. I. O., Rawstron, A. C., Fazi, C., Agathangelidis, A., Villamor, N., Letestu, R., Nomdedeu, J., Palacio, C., Stehlikova, O., Kreuzer, K.-A., et al. (2016) · Leukemia · doi:10.1038/leu.2015.313 · Cited by 248
Self-citationTam, C. S., Allan, J. N., Siddiqi, T., Kipps, T. J., Jacobs, R., Opat, S., Barr, P. M., Tedeschi, A., Trentin, L., Bannerji, R., et al. (2022) · Blood · doi:10.1182/blood.2021014488 · Cited by 248
Shanafelt, T. D., Wang, X. V., Hanson, C. A., Paietta, E. M., O’Brien, S., Barrientos, J., Jelinek, D. F., Braggio, E., Leis, J. F., Zhang, C. C., et al. (2022) · Blood · doi:10.1182/blood.2021014960 · Cited by 242
Self-citationFixed-Duration Ibrutinib-Venetoclax in Patients with Chronic Lymphocytic Leukemia and Comorbidities
Kater, A. P., Owen, C., Moreno, C., Follows, G., Munir, T., Levin, M.-D., Benjamini, O., Janssens, A., Osterborg, A., Robak, T., et al. (2022) · NEJM Evidence · doi:10.1056/evidoa2200006 · Cited by 241
Self-citationWierda, W. G., Allan, J. N., Siddiqi, T., Kipps, T. J., Opat, S., Tedeschi, A., Badoux, X. C., Kuss, B. J., Jackson, S., Moreno, C., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.00807 · Cited by 233
Sharman, J. P., Egyed, M., Jurczak, W. J., et al. (2022) · Leukemia · doi:10.1038/s41375-021-01485-x · Cited by 209
Seymour, J. F., Kipps, T. J., Eichhorst, B. F., D’Rozario, J., Owen, C. J., Assouline, S., Lamanna, N., Robak, T., de la Serna, J., Jaeger, U., et al. (2022) · Blood · doi:10.1182/blood.2021015014 · Cited by 159
Self-citationSoumerai, J. D., Mato, A. R., Doǧan, A., Seshan, V. E., Joffe, E., Flaherty, K., Carter, J., Hochberg, E. P., Barnes, J. A., Hamilton, A. M., et al. (2021) · The Lancet Haematology · doi:10.1016/s2352-3026(21)00307-0 · Cited by 121
Rogers, K. A., Huang, Y., Ruppert, A. S., Abruzzo, L. V., Andersen, B. L., Awan, F. T., Bhat, S. A., Dean, A., Lucas, M. S., Banks, C., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.00491 · Cited by 109
Davids, M. S., Lampson, B. L., Tyekucheva, S., Wang, Z., Lowney, J., Pazienza, S., Montegaard, J. S., Patterson, V., Weinstock, M., Crombie, J. L., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00455-1 · Cited by 104
Flinn, I. W., Gribben, J. G., Dyer, M. J. S., Wierda, W. G., Maris, M. B., Furman, R. R., Hillmen, P., Rogers, K. A., Iyer, S. P., Quillet‐Mary, A., et al. (2019) · Blood · doi:10.1182/blood-2019-01-896290 · Cited by 74
Kater, A. P., Levin, M., Dubois, J. M. N., Kersting, S., Enggaard, L., Veldhuis, G. J., Mous, R., Mellink, C. H. M., van der Kevie-Kersemaekers, A.-M. F., Dobber, J. A., et al. (2022) · The Lancet Oncology · doi:10.1016/s1470-2045(22)00220-0 · Cited by 64
Self-citationHuber, H., Edenhofer, S., von Tresckow, J., Robrecht, S., Zhang, C., Tausch, E., Schneider, C., Bloehdorn, J., Fürstenau, M., Dreger, P., et al. (2022) · Blood · doi:10.1182/blood.2021013208 · Cited by 48
Self-citationCOVID-19 among fit patients with CLL treated with venetoclax-based combinations
Fürstenau, M., Langerbeins, P., Silva, N. D., Fink, A. M., Robrecht, S., von Tresckow, J., Simon, F., Hohloch, K., Droogendijk, J., van der Klift, M., et al. (2020) · Leukemia · doi:10.1038/s41375-020-0941-7 · Cited by 46
Self-citationKersting, S., Dubois, J. M. N., Nasserinejad, K., Dobber, J. A., Mellink, C. H. M., van der Kevie-Kersemaekers, A.-M. F., Evers, L. M., de Boer, F., Koene, H. R., Schreurs, J., et al. (2022) · The Lancet Haematology · doi:10.1016/s2352-3026(22)00034-5 · Cited by 34
Self-citation
Metadata
- Authors
- Eichhorst, B., Niemann, C. U., Kater, A. P., Fürstenau, M., von Tresckow, J., Zhang, C., Robrecht, S., Gregor, M., Juliusson, G., Thornton, P., Staber, P. B., Tadmor, T., Lindström, V., da Cunha-Bang, C., Schneider, C., Poulsen, C. B., Illmer, T., Schöttker, B., Nösslinger, T., Janssens, A., Christiansen, I., Baumann, M., Frederiksen, H., van der Klift, M., Jäger, U., Leys, M. B. L., Hoogendoorn, M., Lotfi, K., Hebart, H., Gaska, T., Koene, H., Enggaard, L., Goede, J., Regelink, J. C., Widmer, A., Simon, F., De Silva, N., Fink, A.-M., Bahlo, J., Fischer, K., Wendtner, C.-M., Kreuzer, K. A., Ritgen, M., Brüggemann, M., Tausch, E., Levin, M.-D., van Oers, M., Geisler, C., Stilgenbauer, S., & Hallek, M.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2023-05-11
- Volume
- 388
- Issue
- 19
- Pages
- 1739-1754
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4376108172
- Cited by
- 305
- References
- 26
- FWCI
- 43.45
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.